Alnylam Pharmaceuticals Dividends and Buybacks
Dividend criteria checks 0/6
Alnylam Pharmaceuticals does not have a record of paying a dividend.
Key information
n/a
Dividend yield
-1.0%
Buyback Yield
| Total Shareholder Yield | -1.0% |
| Future Dividend Yield | 0% |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | n/a |
Recent dividend and buyback updates
No updates
Recent updates
Alnylam Pharmaceuticals Q3 Earnings Preview: Key RNAi Catalysts To Watch
Oct 27Are Investors Undervaluing Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) By 49%?
Sep 12
Alnylam: HELIOS-B Success Priced In Already
Aug 30Analysts Are Upgrading Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) After Its Latest Results
Aug 04Broker Revenue Forecasts For Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Are Surging Higher
Aug 02RNAi: Winning In The Clinic, Now For The Market
Jun 25Upcoming Pivotal HELIOS-B Data Looms Large For Alnylam's Valuation
Jun 03Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Price Is Right But Growth Is Lacking
Mar 19Is Alnylam's HELIOS-B Delay A Red Flag?
Mar 10Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Just Released Its Full-Year Earnings: Here's What Analysts Think
Feb 18Alnylam's Huge Opportunity
Jan 12Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Price Is Out Of Tune With Revenues
Dec 18Unpleasant Surprises Could Be In Store For Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Shares
Jun 23Is Alnylam Pharmaceuticals (NASDAQ:ALNY) Weighed On By Its Debt Load?
Oct 25Alnylam gets FDA nod for expanded use of rare disease drug Oxlumo
Oct 07Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if ALNY's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ALNY's dividend payments have been increasing.
Dividend Yield vs Market
| Alnylam Pharmaceuticals Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (ALNY) | n/a |
| Market Bottom 25% (US) | 1.4% |
| Market Top 25% (US) | 4.3% |
| Industry Average (Biotechs) | 2.3% |
| Analyst forecast (ALNY) (up to 3 years) | 0% |
Notable Dividend: Unable to evaluate ALNY's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ALNY's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate ALNY's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as ALNY has not reported any payouts.